Allurion Technologies, Inc.
ALURD
Other OTC3.47
USD
-0.03
- -
Allurion Technologies, Inc.
ALURD
(Other OTC)
Recent
price
3.47
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Allurion Technologies, Inc. develops, manufactures, markets, and distributes professional weight management solutions and related services for obesity treatment and wellness. Its flagship devices and offerings include the Allurion Elipse program, a swallowable, non-surgical gastric balloon system designed to assist weight loss by occupying space in the stomach and facilitating portion control, along with accompanying support programs, educational materials, and remote monitoring tools. The company provides device development services, clinical research collaborations, and turnkey customer support for healthcare providers, clinics, and wellness centers. Main products and services: Elipse gastric balloon system; Elipse weight management program services; swallowable gastric balloon devices; pre- and post-implantation patient support and education programs; clinical trial collaboration services; data collection and remote monitoring platforms; medical device integration and training for clinicians; treatment planning and monitoring analytics; patient recruitment and adherence support; manufacturing and regulatory compliance services. Latest major company changes: pursues strategic partnerships and alliances to expand global adoption of the Elipse program; completes funding rounds to scale manufacturing, clinical trials, and commercialization; enters new clinical collaborations and distribution agreements in additional geographic regions; expands product portfolio with enhancements to the non-surgical weight loss platform; reorganizes operations to support international commercialization and regulatory approvals; advances regulatory submissions and approvals in multiple markets. Industry and business segments: medical devices, obesity treatment, weight management programs, eHealth and digital health support platforms; healthcare services and patient engagement. Target markets and customers: healthcare providers, obesity treatment clinics, weight-management centers, hospitals, and self-pay patients seeking non-surgical weight loss options. Geographic operations: global presence with activity in North America, Europe, Asia-Pacific, and other regions through direct and partner distributions; manufacturing and R&D located in the United States, with international regulatory and commercial operations. Founding year and headquarters: founded in 20XX; headquarters in the United States. Subsidiaries and parent relationships: operates as an independent publicly traded company with partnerships and collaborations within the medical device and digital health ecosystem.